Dr. William E Gillanders, M.D.
Claim this profileWashington University School of Medicine
Studies Breast Cancer
Studies Pancreatic Cancer
12 reported clinical trials
24 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
ER positive
Stage IV
2Pancreatic Cancer
Stage II
Stage III
Stage I
Affiliated Hospitals
Clinical Trials William E Gillanders, M.D. is currently running
Personalized DNA Vaccine + PD-1 Blockade
for Glioblastoma
This is a single institution, open-label, multi-arm, phase I study assessing the safety and immunogenicity of a personalized neoantigen-based personalized DNA vaccine combined with PD-1 blockade therapy in subjects with newly diagnosed, MGMT promoter unmethylated glioblastoma (GBM). Immune checkpoint blockade, specifically those targeting the PD-1/PD-L1 pathways, has shown efficacy in multiple solid and hematologic malignancies. Furthermore, as has been demonstrated in metastatic melanoma, combining PD-1/PD-L1 blockade with other immune checkpoint inhibitors has shown improved objective response rates, though there is a significant increase in serious immune-related adverse events. As such, current trials are exploring different doses, administration schedules, and immune checkpoint agents. One alternative approach, however, is to introduce a tumor-directed therapy such as a personalized neoantigen vaccine combined with these immune modulating agents (i.e. immune checkpoint blocking antibodies) to maximize the tumor-specific response but minimize the toxicity associated with increasing non-specific systemic immune activation by generating a potent and focused neoantigen specific immune response. This study will test the hypothesis that a personalized neoantigen DNA vaccine in combination with concurrent administration of immune checkpoint blockade therapy will enhance the magnitude and breadth of neoantigen-specific T cell responses while maintaining an acceptable safety profile. The overall goal of this study is to identify the optimal vaccine plus adjuvant platform that can be tested in a subsequent phase II study to determine the efficacy of a personalized neoantigen vaccine approach in patients with GBM.
Recruiting1 award Phase 1
Personalized Cancer Vaccine
for Bladder Cancer
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Recruiting1 award Phase 17 criteria
More about William E Gillanders, M.D.
Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments William E Gillanders, M.D. has experience with
- Durvalumab
- Personalized Neoantigen DNA Vaccine
- Personalized Cancer Vaccine (PCV)
- Neoantigen Synthetic Long Peptide Vaccine
- Optimized Neoantigen Synthetic Long Peptide Vaccine
- Poly-ICLC
Breakdown of trials William E Gillanders, M.D. has run
Breast Cancer
Pancreatic Cancer
Glioblastoma
Bladder Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does William E Gillanders, M.D. specialize in?
William E Gillanders, M.D. focuses on Breast Cancer and Pancreatic Cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are ER positive.
Is William E Gillanders, M.D. currently recruiting for clinical trials?
Yes, William E Gillanders, M.D. is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that William E Gillanders, M.D. has studied deeply?
Yes, William E Gillanders, M.D. has studied treatments such as Durvalumab, Personalized neoantigen DNA vaccine, Personalized Cancer Vaccine (PCV).
What is the best way to schedule an appointment with William E Gillanders, M.D.?
Apply for one of the trials that William E Gillanders, M.D. is conducting.
What is the office address of William E Gillanders, M.D.?
The office of William E Gillanders, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.